Lonza Group Ltd., a leading supplier to the pharmaceutical, healthcare and life science industries, and Arch Chemicals Inc., a global biocides company, have signed an agreement in which Lonza will buy 100 percent of Arch Chemicals’ outstanding shares of common stock at a price of $47.20 per share in cash, an enterprise value of $1.4 billion.